Tempest Therapeutics (TPST) Projected to Post Quarterly Earnings on Wednesday

Tempest Therapeutics (NASDAQ:TPST) is expected to announce its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.32) per share for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

Tempest Therapeutics (NASDAQ:TPST) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.04). On average, analysts expect Tempest Therapeutics to post ($0.83) EPS for the current fiscal year and ($0.90) EPS for the next fiscal year.

Tempest Therapeutics Stock Up 0.1%

TPST stock opened at $0.51 on Wednesday. The business’s 50-day moving average price is $0.85 and its 200-day moving average price is $1.55. Tempest Therapeutics has a twelve month low of $0.50 and a twelve month high of $11.12.

Analysts Set New Price Targets

A number of analysts have recently commented on TPST shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Tempest Therapeutics in a research note on Friday, October 9th. Wall Street Zen raised Tempest Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Reduce”.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. The company’s approach is designed to address both tumor cells and the immune environment surrounding them, with the goal of stimulating antitumor immune responses and improving the effectiveness of cancer treatment.

Tempest’s pipeline includes TPST-1120, an orally administered, selective antagonist of peroxisome proliferator-activated receptor alpha (PPARα). The company has evaluated TPST-1120 in clinical studies involving advanced solid tumors, including hepatocellular carcinoma, and has investigated its use in combination with other cancer therapies.